LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP5 | 3 | E03 | 72 | hr | 2543 | 2515 | 5760 | 0.4366 | -0.0095 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 1 | C02 | 72 | hr | 2543 | 1296 | 5258 | 0.2464 | -0.4745 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 2 | C02 | 72 | hr | 2543 | 1618 | 5438 | 0.2975 | -0.3381 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 3 | C02 | 72 | hr | 2543 | 1473 | 5557 | 0.2651 | -0.3839 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 1 | E02 | 72 | hr | 2543 | 1298 | 5734 | 0.2264 | -0.4365 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 2 | E02 | 72 | hr | 2543 | 977 | 5761 | 0.1696 | -0.5556 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 3 | E02 | 72 | hr | 2543 | 1227 | 5760 | 0.2130 | -0.4610 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP6 | 1 | C01 | 72 | hr | 2543 | 987 | 5258 | 0.1877 | -0.5948 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP6 | 2 | C01 | 72 | hr | 2543 | 1028 | 5438 | 0.1890 | -0.5623 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP6 | 3 | C01 | 72 | hr | 2543 | 1034 | 5557 | 0.1861 | -0.5499 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP5 | 1 | E01 | 72 | hr | 2543 | 1078 | 5734 | 0.1880 | -0.5190 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP5 | 2 | E01 | 72 | hr | 2543 | 650 | 5761 | 0.1128 | -0.6854 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP5 | 3 | E01 | 72 | hr | 2543 | 1083 | 5760 | 0.1880 | -0.5151 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 1 | P18 | 72 | hr | 2543 | 4754 | 5734 | 0.8290 | 0.7045 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 2 | P18 | 72 | hr | 2543 | 4637 | 5761 | 0.8048 | 0.6638 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 3 | P18 | 72 | hr | 2543 | 5257 | 5760 | 0.9125 | 0.8507 |
| SK-BR-3 | Brivanib | 0.12 | uM | LJP5 | 1 | P17 | 72 | hr | 2543 | 4762 | 5734 | 0.8304 | 0.7069 |
| SK-BR-3 | Brivanib | 0.12 | uM | LJP5 | 2 | P17 | 72 | hr | 2543 | 4981 | 5761 | 0.8645 | 0.7678 |
| SK-BR-3 | Brivanib | 0.12 | uM | LJP5 | 3 | P17 | 72 | hr | 2543 | 5143 | 5760 | 0.8928 | 0.8166 |
| SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 1 | P16 | 72 | hr | 2543 | 4723 | 5734 | 0.8236 | 0.6950 |
| SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 2 | P16 | 72 | hr | 2543 | 5026 | 5761 | 0.8724 | 0.7814 |
| SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 3 | P16 | 72 | hr | 2543 | 4921 | 5760 | 0.8542 | 0.7499 |
| SK-BR-3 | Brivanib | 1.11 | uM | LJP5 | 1 | P15 | 72 | hr | 2543 | 5260 | 5734 | 0.9173 | 0.8580 |
| SK-BR-3 | Brivanib | 1.11 | uM | LJP5 | 2 | P15 | 72 | hr | 2543 | 4815 | 5761 | 0.8357 | 0.7178 |
| SK-BR-3 | Brivanib | 1.11 | uM | LJP5 | 3 | P15 | 72 | hr | 2543 | 5573 | 5760 | 0.9674 | 0.9446 |